Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Latest Information Update: 01 Dec 2023
At a glance
- Drugs SenL-T7 (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
- 01 Dec 2023 Results (n=60 from studies NCT04572308 and NCT04916860) assessing safety and efficacy of patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy published in the American Journal of Hematology
- 15 Jun 2023 Results (n=10 from NCT04572308 &NCT04916860) assessing the efficacy and safety of NS7CAR T-cells for relapsed or refractory (R/R) T-ALL/LBL with CNS involvement in phase I/II clinical trial presented at the 28th Congress of the European Haematology Association
- 30 Mar 2023 Status changed from recruiting to active, no longer recruiting.